Stock TEQ TERRANUEVA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Terranueva Corporation

Equities

TEQ

CA88105H1010

Biotechnology & Medical Research

Delayed Canadian Securities Exchange
Other stock markets
 14:40:25 2024-02-05 EST 		5-day change 1st Jan Change
0.03 CAD +50.00% Intraday chart for Terranueva Corporation -.--% +20.00%
2023 Terranueva Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023 CI
2023 Terranueva Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023 CI

Valuation

Fiscal Period: September 2019 2020 2021 2022
Capitalization 1 14.12 3.284 3.218 1.609
Enterprise Value (EV) 1 16.84 7.649 8.215 5.854
P/E ratio - -1.55 x -1.26 x -0.49 x
Yield - - - -
Capitalization / Revenue - - - 25,838,253 x
EV / Revenue - - - 94,016,974 x
EV / EBITDA -6,553,335 x -5,396,894 x -5,657,756 x -2,919,109 x
EV / FCF -9,173,557 x -9,075,446 x -8,404,232 x -3,195,399 x
FCF Yield -0% -0% -0% -0%
Price to Book - -15 x -2.4 x -0.48 x
Nbr of stocks (in thousands) 32,845 32,845 45,970 45,970
Reference price 2 - 0.1000 0.0700 0.0350
Announcement Date 20-01-28 21-01-28 22-01-28 23-05-05
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2018 2019 2020 2021 2022
Net sales - - - - 0.0623
EBITDA - -2.57 -1.417 -1.452 -2.006
EBIT 1 -0.522 -2.772 -1.721 -1.766 -2.275
Operating Margin - - - - -3,653.59%
Earnings before Tax (EBT) 1 -0.7362 -5.494 -2.125 -2.212 -3.776
Net income 1 -0.6711 -5.494 -2.125 -2.191 -3.314
Net margin - - - - -5,322.62%
EPS 2 -7.314 -0.1673 -0.0647 -0.0556 -0.0721
Free Cash Flow - -1.836 -0.8429 -0.9775 -1.832
FCF margin - - - - -2,942.26%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 19-01-24 20-01-28 21-01-28 22-01-28 23-05-05
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2018 2019 2020 2021 2022
Net Debt 1 3.92 2.72 4.36 5 4.25
Net Cash position 1 - - - - -
Leverage (Debt/EBITDA) - -1.058 x -3.08 x -3.442 x -2.117 x
Free Cash Flow - -1.84 -0.84 -0.98 -1.83
ROE (net income / shareholders' equity) - -871% -293% 281% 141%
ROA (Net income/ Total Assets) - -32.8% -18.9% -20.8% -38.5%
Assets 1 - 16.75 11.27 10.51 8.607
Book Value Per Share 2 -0.0100 0.0500 -0.0100 -0.0300 -0.0700
Cash Flow per Share 2 0.0300 0.0200 0.0100 0 0.0100
Capex 1 0.26 1.48 0.03 0.02 0.04
Capex / Sales - - - - 60.08%
Announcement Date 19-01-24 20-01-28 21-01-28 22-01-28 23-05-05
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TERRANUEVA CORPORATION Stock Terranueva Corporation
+20.00% 1.01M
MODERNA, INC. Stock Moderna, Inc.
+34.58% 51.07B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-7.78% 38.78B
LONZA GROUP AG Stock Lonza Group AG
+35.88% 38.61B
CELLTRION, INC. Stock Celltrion, Inc.
-10.62% 27.32B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.82% 26.35B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-18.74% 19.46B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+40.75% 13.58B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.20% 12.46B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-3.61% 11.75B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TEQ Stock
  4. Financials Terranueva Corporation